Guido J. Neels

This profile gathers the share dealings of Guido J. Neels across 3 companies, led by Axogen, Inc., Bioventus Inc. and Elutia Inc. Between 19 May 2021 and 2 June 2026, the trades on record add up to 19 filings.

In open-market terms, that means 3 purchases worth €87k on one side and 1 sale worth €38k on the other. The net balance comes to €49k on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 1 share grant and 14 option exercises. So far in 2026, the count stands at 2 purchases and no sales.

The median purchase comes to €17k. Of 3 purchases, 1 formed part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 4 June 2026: an option exercise, in Bioventus Inc. The clock since the last published purchase (2 February 2026) now reads 258 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.